Sympathetic crashing acute pulmonary edema (SCAPE) is the extreme end of the spectrum of acute pulmonary edema. It is important to understand this disease as it is relatively common in the emergency department (ED) and has better outcomes when managed appropriately. The patients have an abrupt redistribution of fluid in the lungs, and when treated promptly and effectively, these patients will rapidly recover. Noninvasive ventilation and intravenous nitrates are the mainstay of treatment which should be started within minutes of the patient’s arrival to the ED. Use of morphine and intravenous loop diuretics, although popular, has poor scientific evidence.

**Keywords:** Diuretics, emergency department, high-dose nitroglycerin, noninvasive ventilation, pulmonary edema, sympathetic crashing acute pulmonary edema

**Introduction**

Acute heart failure syndrome (AHFS) is a common underlying cause for dyspnea in patients presenting to emergency departments (EDs) throughout the globe.[1,2] The clinical syndrome is characterized by elevated cardiac filling pressures, causing rapid accumulation of fluid in pulmonary interstitial and alveolar spaces.

The spectrum of patients presenting with AHFS is wide, ranging from mild pulmonary edema to cardiogenic shock. This particular subset of patients with sympathetic crashing acute pulmonary edema (SCAPE)[3] have severe AHFS and present with dramatic onset and rapid progression of symptoms (flash pulmonary edema), giving the emergency physicians a narrow time window to intervene and improve patient outcome.

Flash pulmonary edema is the most severe clinical scenario of all the AHFS.[4] It is known by various names: Crashing pulmonary edema, severe acute pulmonary edema, acute decompensated heart failure, and so on. Due to the central role of increased sympathetic activity in the pathophysiology of this subset of patients, SCAPE is a better terminology for understanding the syndrome of rapid onset, life-threatening pulmonary edema.

We hereby present the review of various underlying pathophysiologic mechanisms as well as approach to emergent treatment of patients with SCAPE.

**Methods**

The literature search was done using PubMed and Google Scholar. The search was done using the following terms flash pulmonary edema, acute pulmonary edema, AHFS, high-dose nitroglycerin (NTG), and noninvasive ventilation (NIV). Abstract was read for each of the searched articles. The appropriately considered articles were downloaded using our institute portal. Different sections of 36 articles were read, and a review was written.

**Pathophysiology**

Pulmonary fluid homeostasis is equilibrium between forces that drive fluid into the alveolar spaces and the...
mechanisms responsible for its clearance. AHFS is associated with increased cardiac filling pressures, which are transmitted to pulmonary capillaries and eventually drive intravascular fluid into pulmonary interstitium and alveoli. There are three stages of progression of AHFS:

- Stage 1: Distension of small pulmonary capillaries due to increased left atrial pressure
- Stage 2: Interstitial edema
- Stage 3: Flooding of alveolar space causing hypoxia.

Underlying pathophysiologic mechanisms are similar for AHFS and SCAPE. However, there are notable differences between the two. SCAPE develops over minutes-to-hours into a life-threatening condition. Important distinguishing features are the pathophysiologic changes resulting in stress failure and increased permeability of the pulmonary capillaries causing abrupt onset and rapid progression.

Sympathetic system is an important factor in cardiovascular physiology. Left ventricular dysfunction predisposes to abrupt increase in sympathetic tone and release of catecholamines that can precipitate flash pulmonary edema. Increased catecholamines cause increased heart rate and decreased diastolic time. It causes activation of renin–angiotensin–aldosterone system (RAAS), which further worsens diastolic stiffening and increased diastolic pressures causing pulmonary fluid overload. Increased sympathetic tone adversely affects the pulmonary circulation by increasing permeability and/or provoking stress failure of the pulmonary capillaries. Other factors contributing to flash pulmonary edema include decreased nitric oxide and increased endothelin activity.

**Clinical Features and Diagnosis**

Diagnosis of SCAPE is purely clinical. Patients with SCAPE present with a relatively abrupt onset of shortness of breath which progresses over minutes-to-hours into life-threatening pulmonary edema. Patients present with extremely severe respiratory distress. They are restless, diaphoretic, and hypoxic on arrival to the ED. There are tachycardia and marked hypertension, suggesting elevated sympathetic activity in vivo. SCAPE is a subset of hypertensive heart failure, and hence almost always presents with high systolic blood pressure. Extensive bilateral crepitations are present of chest auscultation.

These patients are too unstable and orthopneic to lie down for performing a 12-lead ECG at the time of arrival. Cardiac sensitive troponin is elevated in significant proportion of patients with heart failure and is associated with increased mortality. Bedside, screening echocardiography during the acute presentation would reveal preserved (ejection fraction >0.5), suggesting that underlying mechanism is worsening of diastolic dysfunction.

**Management Principles**

SCAPE is not a diagnostic dilemma. Early recognition and prompt initiation of treatment is the key to preventing morbidity and mortality. Immediate ED management of severe pulmonary edema has its impact on subsequent clinical course, rates of invasive mechanical ventilation, and rates of Intensive Care Unit (ICU) admissions. Various options for initial treatment include NTG, NIV, diuretics, and morphine.

**Invasive ventilation**

Intubation and use of invasive mechanical ventilation can be averted if high-dose NTG and NIV are rapidly initiated in the emergency room. When a patient presents late with impending respiratory fatigue or without spontaneous breathing efforts, then the attending physician should proceed with intubation. Intubation may be difficult in view of extreme agitation of these patients. Patients are agitated and orthopneic on arrival making it difficult to preoxygenate and position the patient for tube placement, thereby decreasing the first pass success. Preexisting hypoxia and inadequate preoxygenation may lead to increased risk of peri-intubation cardiac arrest.

**Noninvasive ventilation**

Two commonly used forms of NIV are bi-level positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP). NIV provides oxygenation, stents open the flooded alveoli and decreases dead space ventilation. It decreases preload and afterload, thereby decreasing cardiac oxygen demand workload. In addition, BiPAP also decreases the work of breathing during inspiration in severely orthopneic patients with SCAPE. NIV is associated with decreased rates of invasive mechanical ventilation and decreased mortality in patients with cardiogenic pulmonary edema, thereby decreasing the rates of associated complications.

The application of NIV is an art in itself. All physicians should personally apply NIV mask to the patient. An important aspect of NIV treatment in SCAPE is its early application. Rapidly screen for contraindications for the use of NIV, in the absence of which, NIV mask should be applied as soon as the patient is diagnosed of having SCAPE. The mask should be held and not strapped to the patient’s face. When the two modes
of NIV (CPAP and BiPAP) are compared, there is no major difference in efficacy or safety, for the treatment of cardiogenic pulmonary edema in patients presenting to the ED.\[25,28\] One effective way of using NIV pressures in treatment of SCAPE is to begin with expiratory pressures (CPAP/expiratory positive airway pressure) of 6 cmH\(_2\)O which is rapidly increased to 12–14 cmH\(_2\)O. Once there is a clinical improvement, pressures are then sharply decreased to 6–8 cmH\(_2\)O and then titrated to patient’s requirements. NIV interfaces include nasal and oronasal masks. Both are associated with similar improvements in gas exchange and avoidance of intubation.\[29\]

**Nitrates**

Nitrates have a beneficial effect in AHFS by causing preload reduction, thereby decreasing the cardiac workload. They can be used sublingual until an intravenous access is gained. Initial intravenous dose of NTG in patients with cardiogenic pulmonary edema is 10–20 µg/min infusion with gradual up-titration. Nitrates cause only venodilatation in these dose ranges, with higher doses required to cause arteriodilatation.\[30\] Nitrates can cause hypotension, especially in volume-depleted patients and should be avoided in hypotensive patients.

However, the use of nitrates in SCAPE differs from that of other varieties of AHFS. Intense sympathetic activity causes both venous and arterial tone to increase significantly causing diastolic failure. Hence, the aim is to decrease the afterload at the earliest to cut the vicious cycle caused by sympathetic upsurge. Thus, initiating the treatment with low-dose nitrates (venodilatory doses) with gradual titration does little to target the underlying pathophysiology. Furthermore, it takes more time to reach effective doses, thereby missing important window for treatment of these patients.

Preferred treatment of SCAPE patients would target increased afterload using high doses of nitrates on arrival. In a feasibility study, Levy et al. used 2 mg boluses of NTG every 3 min (666 µg/min) for first 30 min in patients presenting to the ED with severe decompensated heart failure and hypertension. These were compared to the patients receiving NTG infusion beginning at 30 µg/min with up-titration. There were decreased rates of endotracheal intubation and ICU admissions in high-dose NTG group. Only one patient developed hypotension in high-dose NTG group, which was managed with a crystalloid bolus with no further adverse events.\[31\] Although the study was nonrandomized and was open label, it gives valuable information about the efficacy and safety of high-dose nitrates in SCAPE.

Various other studies have demonstrated the efficacy and safety of high-dose nitrates for the treatment of severe cardiogenic pulmonary edema.\[30,32,33\] Thus, precipitous hypotension is unusual with high-dose NTG and even if it occurs, stopping the infusion transiently, with a crystalloid bolus is all that would be required for treatment.

A feasible method of use of high-dose nitrates is thus followed in patients with SCAPE. An initial “bolus” dose of 500–1000 µg given over 2 min can be safely used.\[30–32\] This is followed by high-dose infusion at 100 µg/min with rapid up-titration till there is a clinical improvement, the usual target systolic BP being 140 mmHg. Then, the infusion rate is sharply reduced and slowly discontinued as patient’s condition allows [Figure 1].

**Morphine**

Morphine has long been used as an initial agent for the treatment of cardiogenic pulmonary edema. It causes venodilatation, thereby decreasing preload;\[34\] it decreases anxiety and pain, thereby decreasing the myocardial oxygen demand and hence has potential benefit during AHFS. However, morphine can cause respiratory depression,\[35\] which may lead to worsened hypoxia and respiratory arrest.

In some reports, morphine use has been associated with bad patient outcome in the form of increased rates of mechanical ventilation and ICU use.\[19,36\] Thus, role of morphine in severe acute pulmonary edema is largely nonevidence based and controversial. However, it can be useful in conditions where analgesia is desired, such as myocardial ischemia causing AHFS.

**Diuretics**

Loop diuretics such as furosemide have been primarily used in the management of acute pulmonary edema. The diuretic effect of furosemide starts in 30 min and peaks in 1.5 h. However, despite its popularity, there is only poor evidence for its benefit.\[37\]
evidence supporting its current use in SCAPE patients.[37]
In fact, it may be detrimental to this subset of patients
due to its stimulation of RAAS and sympathetic nervous
system.[37] Furthermore, patients with SCAPE may be
systemically hypovolemic or euvolemic due to long-term
use of diuretics and high-dose intravenous diuretics may
cause further deterioration in clinical condition.[4]

Current evidence does not support nor does it
completely abolish the use of diuretics in SCAPE patients
and carefully designed studies may be required to that
purpose. Currently, it is recommended as an additional
regimen to vasodilator therapy using NTG which
remains the mainstay of treatment for SCAPE.

Conclusion

The need to understand this pathology and its very
prompt management in the ED cannot be emphasized
more. SCAPE is the extreme end of the spectrum of
acute pulmonary edema. It is one of those high-yield
emergencies presenting to the ED which when treated
quickly and effectively will not only save a life but
also obviate the need for intubation and ICU care. In
this subset of patients, there is redistribution of fluid
in the body mainly in the lung while patient may still
be hypovolemic or euvolemic.[4] The patients present
to the emergency with extreme respiratory distress
associated with restlessness, diaphoresis, and high
blood pressure (usually systolic above 180 mmHg). The
mainstay of management is NIV and high-dose nitrate
infusions within minutes of the patient’s arrival to the
 ED. Use of intravenous diuretics and morphine, although
popular, is not supported by good scientific evidence.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Fromm RE Jr, Varon J, Gibbs LR. Congestive heart failure and pulmonary
edema for the emergency physician. J Emerg Med 1995;13:71-87.
2. Howlett JG. Current treatment options for early management in acute
decompensated heart failure. Can J Cardiol 2008;24 Suppl H: 9B-14B.
3. Weingart S. Emerit Podcast 1, Sympathetic Crashing Acute Pulmonary
Edema. Available from: http://www.emerit.org. [Last accessed on 2016
Oct 30].
4. Melazan A, Ghergoziolo M, Piña HL, Harjola VP, Hellenberg SM, Folliath F, et al. Practical recommendations for prehospital and early-
in-hospital management of patients presenting with acute heart failure
syndromes. Crit Care Med 2008;36 1 Suppl:S129-39.
5. Sartori C, Allemann Y, Scherrer U. Pathogenesis of pulmonary
edema: Learning from high-altitude pulmonary edema. Respir Physiol
Neurobiol 2007;159:338-49.
6. Ware LP, Matthey MA. Clinical practice. Acute pulmonary edema. N Engl J Med 2005;353:2788-96.
7. West JB, Mathieu-Costello O. Stress failure of pulmonary capillaries in
the intensive care setting. Schweiz Med Wochenschr 1992;122:751-7.
8. Lenders JW, Eisenhofer G, Mannelli M, Pweek K. Phaeochromocytoma.
Lancet 2005;366:665-75.
9. Yamanaka O, Yasunuma F, Nakamura T, Ohno A, Endo Y, Yoshimi K, et al. “Myocardial stunning”-like phenomenon during a
crisis of phaeochromocytoma. Jpn Circ J 1994;58:737-42.
10. Rimoli SF, Yizengawlaya M, Allemann Y, Messerli F. Flash pulmonary
edema. Prog Cardiovasc Dis 2009;52:249-59.
11. Krasney JA. A neurogenic basis for acute altitude illness. Med Sci
Sports Exerc 1994;26:205-208.
12. Chopra A, Gavíña TP, Sifakis XM, Hassler LJ, Offert IM, Wagner H, et al. Effect of prolonged, heavy exercise on pulmonary gas exchange
in athletes. J Appl Physiol 1988;85:1523-32.
13. Kramer K, Kirkman P, Kittman DW, Little WC. Flash pulmonary edema:
Association with hypertension and reoccurrence despite coronary
revascularization. Am Heart J 2000;140:451-5.
14. Gandhi SK, Powers JC, Nuneim AM, Fowle K, Kittman DW,
Rankin KM, et al. The pathogenesis of acute pulmonary edema
associated with hypertension. N Engl J Med 2001;344:17-22.
15. Misroz E, Calzolari C, Pan B. Curvelating cardiae troponin I in severe
congestive heart failure. Circulation 1997;96:2925-8.
16. Perna ER, Macin SM, Perras JL, Pantele A, Farias ES, Furlaneuco JR,
et al. Cardiac troponin T levels are associated with poor short- and
long-term prognosis in patients with acute cardiogenic pulmonary
edeme. Am Heart J 2002;143:814-20.
17. Grossman W. Defining diastolic dysfunction. Circulation 2000;101:2020-1.
18. Danterman KW, Massie BM, Gheorghiade M. Heart failure associated
with preserved systolic function: A common and costly clinical entity.
Am Heart J 1998;135:8310-9.
19. Saezetti A, Ramousa E, Moakes ME, McDermott P, Moyer V. Effect of
ED management on ICU use in acute pulmonary edema. Am J Emerg
Med 1999;17:571-4.
20. Mort TC. The incidence and risk factors for cardiac arrest during
emergency tracheal intubation: A justification for incorporating the
ASA Guidelines in the remote location. J Clin Anesth 2004;16:508-16.
21. Heffner AC, Swords DS, Neale MN, Jones AE. Incidence and
factors associated with cardiac arrest complicating emergency airway
management. Resuscitation 2013;84:1500-4.
22. Lenique F, Habas M, Lofaso F, Dubois-Randé JL, Harf A, Bredaud E.
Ventilatory and hemodynamic effects of continuous
positive airway pressure in left heart failure. Am J Respir Crit Care
Med 1997;155:500-5.
23. Hess DR. The evidence for noninvasive positive-pressure ventilation in
the care of patients in acute respiratory failure: A systematic review of
the literature. Respir Care 2004;49:180-29.
24. Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Non-invasive ventilation
in acute cardiogenic pulmonary oedema. Postgrad Med J 2005;81:637-43.
25. Collins SR, Mielczuk LM, Whittingham HA, Boseley ME, Schramm DR, Storros AB. The use of noninvasive ventilation in
emergency department patients with acute cardiogenic pulmonary
edema: A systematic review. Ann Emerg Med 2006;48:260-9.
26. Crane SD, Elliott MW, Gilligan P, Richards K, Gray AJ. Randomised
controlled comparison of continuous positive airways pressure, bilevel
non-invasive ventilation, and standard treatment in emergency
department patients with acute cardiogenic pulmonary oedema. Emerg
Med J 2004;21:155-61.
27. Kelly CA, Newby DE, McDonagh TA, Mackay TW, Barr J, Boon NA,
et al. Randomised controlled trial of continuous positive airway
pressure and standard oxygen therapy in acute pulmonary oedema;
effects on plasma brain natriuretic peptide concentrations. Eur Heart
J 2002;23:1379-86.
28. Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J;
CPO Trialists. Noninvasive ventilation in acute cardiogenic pulmonary
edema. N Engl J Med 2008;359:142-51.
29. Kwok H, McCormack J, Ceco R, Houtchens J, Hill NS. Controlled trial of oronasal versus nasal mask ventilation in the treatment of acute respiratory failure. Crit Care Med 2003;31:468-73.
30. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998;351:389-93.
31. Levy P, Compton S, Welch R, Delgado G, Jennett A, Penugonda N, et al. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: A feasibility and outcome analysis. Ann Emerg Med 2007;50:144-52.
32. Sharon A, Shirer I, Kaluski E, Moshkovitz Y, Milovanov O, Polak R, et al. High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. J Am Coll Cardiol 2000;36:832-7.
33. Nashed AH, Allegra JR. Intravenous nitroglycerin boluses in treating patients with cardiogenic pulmonary edema. Am J Emerg Med 1995;13:612-3.
34. Visnara LA, Leaman DM, Zelis R. The effects of morphine on venous tone in patients with acute pulmonary edema. Circulation 1976;54:335-7.
35. Chambers JA, Baggoley CJ. Pulmonary oedema – Prehospital treatment. Caution with morphine dosage. Med J Aust 1992;157:326-8.
36. Sosnowski MA. Review article: Lack of effect of opiates in the treatment of acute cardiogenic pulmonary oedema. Emerg Med Australas 2008;20:384-90.
37. Felker GM, O’Connor CM, Braunwald E; Heart Failure Clinical Research Network Investigators. Loop diuretics in acute decompensated heart failure: Necessary? Evil? A necessary evil? Circ Heart Fail 2009;2:56-62.